The associations between psoriasis, metabolic syndrome and cardiovascular events are increasingly recognized. Studies have shown decreased cardiovascular events with the treatment of methotrexate and anti-tumor necrosis factor, however, effects of interleukin (IL)-12/23 blockade remain debatable. Our study investigated the effect of IL-12/23 blockade on the metabolic parameters in patients with psoriasis. We performed a retrospective cohort study to assess 93 consecutive patients with moderate to severe plaque type psoriasis who received IL-12/23 blockade (ustekinumab) for 24 weeks between January 2012 and May 2016. Metabolic parameters and disease activity (Psoriasis Area and Severity Index [PASI] score) at baseline and 24 weeks of treatment were collected. At week 24, the disease activity improved significantly (P < 0.0001), with a significant reduction of erythrocyte sedimentation rate. Conversely, body mass index was significantly elevated in PASI-75 responders at week 24 of treatment and was independent of disease severity. Fasting sugar and triglyceride levels were also elevated at week 24 in both PASI-75 responders and PASI-75 non-responders. Cholesterol, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) remained unchanged. These metabolic parameters were not correlated with the improvement in disease severity after ustekinumab treatment. Nonetheless, the atherogenic index, LDL/HDL ratio and cholesterol/HDL ratio remained unchanged. Male sex and cigarette smoking are predictors of elevated plasma triglyceride levels. Our results suggest that despite tremendous improvement in disease activity after ustekinumab treatment, obesity, fasting sugar and hypertriglyceridemia still present in these patients. Regular screening of lipid profile, obesity control and smoking cessation are advised during the treatment of ustekinumab especially in male psoriatic patients with predisposing cardiovascular risks.
INTRODUCTION
Psoriasis is a chronic inflammatory skin disorder that affects approximately 1-3% of the general population. 1, 2 Patients with psoriasis vulgaris are known to have increased mortality rates compared with the general population, and cardiovascular events are among the most important cause of death in patients with severe psoriasis. [3] [4] [5] [6] An increased risk of obesity and metabolic syndrome was found in psoriasis, and these were established risk factors for cardiovascular events. 5, 7 Severe psoriasis is correlated with metabolic syndrome. 8 Studies suggested that chronic systemic inflammation plays a key role in metabolic disorders and psoriasis. 9, 10 Psoriasis and atherosclerosis both share a common upregulation of T-helper (Th)1 and Th17 cytokines, systemic expression of adhesion molecules and endothelins. 10 Through improvement in the disease activity, one would expect an improvement in the lipid profiles, atherosclerosis and cardiovascular events. Disease activity suppression with methotrexate and anti-tumor necrosis factor (TNF) was associated with reduced cardiovascular risk. 11 Interestingly, previous reports have shown increased levels of total cholesterol (Chol) and triglyceride following treatment of anti-TNF therapy without affecting the atherogenic index. [12] [13] [14] To date, reports of the effects of anti-IL-12/23 on metabolic parameters and cardiovascular risk are still limited and have been rather controversial. 15 Because obesity and dyslipidemia were reversible risk factors for cardiovascular events, the aim of this study was to ascertain the effects of IL-12/23 blockade on metabolic parameters and obesity by the disease activity and treatment responses in patients with psoriasis. 
METHODS

RESULTS
A roster of 93 consecutive patients with moderate to severe plaque type psoriasis were included in this study. All patients had initially a high disease activity (PASI score, >10) that justified the use of ustekinumab. The demographic characteristics of these patients at baseline including age, BMI, sex, pre/post-menopause, smoking, alcoholism, disease duration and underlying comorbidities are described in Table 1 . The mean age at treatment was 41.86 AE 10.56 years with an average disease duration of 15.21 AE 8.4. Male sex (71%) was slightly higher than female (29%) (P = 0.77). The baseline age, disease duration, sex, comorbidities and BMI were similar in both PASI-75+ and PASI-75À (all P > 0.05). All patients tolerated ustekinumab infusions throughout the study with no adverse reactions. No significant changes in physical activity, diet, smoking/alcohol habit or dose of background medications were registered during the study period.
Psoriasis Area and Severity Index score improved significantly over the study period from a week 0 mean of 21.35 AE 11.55 to 6.87 AE 6.81 at week 24 (P < 0.0001 (Table S1 ). Subsequently, we performed a multiple linear regression to investigate the predictors of serum triglyceride level elevation in these patients as shown in Table 3 . Our results show that male sex and smokers are significantly correlated with the elevation of triglyceride levels, whereas BMI, PASI-75 response, alcohol and the presence of comorbidities were not.
DISCUSSION
Psoriasis is a chronic inflammatory disease that is more than "skin deep". Associations between psoriasis and metabolic comorbidities such as obesity, hyperlipidemia, diabetes and cardiovascular events have been well demonstrated. 1, 16, 20 The "psoriatic march" was proposed by Boehncke et al. 17 to describe the evolution of metabolic syndrome to cardiovascular events in psoriatic disease. 18 The key mediators to the pathogenesis of psoriasis, obesity, metabolic syndrome and cardiovascular events all lies in chronic Th1 inflammation. 19 Through controlling psoriasis disease activity, one would expect to provide beneficial effects on these metabolic parameters and eventually lower the risk of cardiovascular events. However, only methotrexate and anti-TNF were found to reduce cardiovascular risk in psoriatic patients, whereas the effect of IL-12/23 antagonist to cardiovascular events remains debatable. 11, 20, 21 Tzellos et al. 20 systemically analyzed the major adverse cardiovascular events (MACE) in patient with psoriasis after treatment of ustekinumab or briakinumab, and found that the MACE events appear to increase in both anti-IL-12/23 monoclonal antibodies. The study was, however, contradictory to a previous study by Ryan et al. 21 which showed no increased risk of MACE in the treatment arm of anti-IL-12/23 antibodies. The discrepancy in both studies were caused by different meta-analysis methods: Peto and risk difference method, respectively. Lipid profile and BMI are metabolic parameters that are strong, yet reversible predictors of MACE. Studies have shown that anti-TNF improved insulin sensitivity and alters lipid profile in psoriatic patients. 22 To our knowledge, there was no previous report regarding the effect of IL-12/23 antagonist (ustekinumab) on lipid profile, and studies on the impact of BMI and correlation with disease severity were limited. 23, 24 In this study, a significant improvement in disease activity was found at week 24 of ustekinumab treatment. Interestingly, BMI, fasting sugar and triglyceride were significantly elevated at week 24 of treatment. The elevation of BMI and triglyceride were more prominent in the PASI-75+ patients. On subsequent multiple linear regression analysis, we found that serum triglyceride elevation was correlated with male sex and smoking habits. Nevertheless, the lipoprotein ratios including Chol/HDL ratio, LDL/ HDL ratio and AIP, which are good predictors for cardiovascular risks, did not change significantly during the treatment period. 25 Hypertriglyceridemia is a known independent risk factor of cardiovascular disease. 26 We observed a significant correlation between fasting triglyceride and both male sex and cigarette smoking but not with other variables. Cigarette smoking is associated with increased serum triglyceride that portends a higher risk for coronary artery diseases and secondary insulin resistance. 27 Studies have shown that smoking changes the expression of triglyceride-rich lipoprotein causing hypercoagulability and reduced fibrinolysis. 27, 28 These changes are modulated by genetic variation in the glycoprotein IIIa gene. 28 Conversely, an increased prevalence of smoking in psoriatic patients and an increased incidence of psoriasis among smokers have been reported, resulting in a vicious cycle. 29 In this study, we have found that male psoriatic patients are more prone to triglyceride elevation. Studies have shown that male sex, but not female, with hypertriglyceridemia are significantly associated with arterial stiffness that determines coronary artery disease; hence, we should closely monitor and treat these patients to prevent this notorious sequealae. 30 Although yet fully understood, the relationship of pro-inflammatory cytokines in psoriasis and metabolic parameters has been studied. 31, 32 In psoriatic skin, IL-12 and IL-23 induces the differentiation of naive CD4 + T cells into the highly pathogenic Th cells, Th1 and Th17, respectively. 33, 34 These Th cells produce inflammatory cytokines such as TNF-a, IL-17, IL-6 and IL-22. 34, 35 These pro-inflammatory cytokines that are heavily involved in the pathogenesis of psoriasis also play an important role in metabolic regulations. For instance, TNF-a is involved in insulin regulation, lipid metabolism and is overexpressed in obese patients. 35, 36 Also, low levels of IL-10 in psoriatic patients were linked to metabolic syndrome, weight gain and insulin resistance. 37, 38 One would expect an antagonist to these pro-inflammatory cytokines to have an opposite effect, however, studies have reported increased levels of triglycerides in mice treated with anti TNF-a. 39, 40 Significant weight gain and increased BMI was also reported after anti-TNF-a treatment. 41 Furthermore, IL-17 deficiency increases diet-induced obesity and accelerates fatty tissue accumulation. 42 While the effects of IL-12/23 blockade on these metabolic parameters are largely unknown in psoriatic patients, phase 2 studies of ustekinumab have shown a paradoxically increased serum levels of IL-12 up to 13-fold in the first 12 weeks of treatment with a gradual decrease to above-baseline levels at week 32. 15, 42 IL-12 is a pro-atherogenic cytokine that induces the production of serum triglyceride and Chol and causes higher insulin resistance. [43] [44] [45] [46] [47] As opposed to our traditional understanding, this phenomena suggests that anti-cytokine antibodies may produce agonists, rather than antagonist effect, especially in the induction period, which may explain findings of increased triglyceride levels in this study. 46, 47 In conclusion, this study illustrates the effect of IL-12/23 blockade by ustekinumab on metabolic parameters in patients with psoriasis. The present study denotes that despite clinical improvement after ustekinumab treatment, the coronary artery risk factors of BMI and triglyceride levels can still increase. Furthermore, smokers and male sex are two predicting factors of the elevation of triglyceride. These findings suggest that when treating patients with ustekinumab, physicians should still regularly follow up patients' metabolic profiles. Moreover, these patients should be strongly counseled to quit smoking and control obesity to minimize cardiovascular risks associated with psoriasis during the treatment period. 
